⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
globenewswire.com
KYMR
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
globenewswire.com
KYMR
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
globenewswire.com
KYMR
Cancer Stress Protein Helps Tumors Hide From Immunity
prnewswire.com
PFE
BMY
KYMR
AGIO
BDTX
PRTA
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
globenewswire.com
KYMR
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
globenewswire.com
KYMR
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
globenewswire.com
KYMR
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
globenewswire.com
KYMR
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
KYMR